Minimally Invasive Splenectomy for Oncological Diseases of the Spleen

  • Julio Lopez Monclova
  • Carlos Rodriguez Luppi
  • Eduardo Mª Targarona Soler


Laparoscopic splenectomy (LS) has become the gold standard procedure for the treatment of benign hematological disorders not associated with splenomegaly, such as idiopathic thrombocytopenic purpura (ITP) [1, 2]. The great advances in minimally invasive surgery (MIS) that have been made over the last two decades did also benefit patients suffering from hematological malignant diseases However, this patients usually develop splenomegaly and the endoscopic manipulation of bulky organs is technically more challenging, and retrieval of the specimen may prove difficult. Splenomegaly was initially considered a contraindication for LS, thus, many malignant hematological diseases which are associated with an enlarged spleen were traditionally reserved for open splenectomy (OS) with its associated increased morbidity. Improvements and refinement of LS techniques have resulted in the ability to remove an enlarged spleen using the laparoscopic approach and preserving all the advantages of the MIS [3–5].


Laparoscopy Spleen Cancer Splenomegaly 

Supplementary material

Video 32.1.

Hand assisted splenectomy (HALS) (MPG 23982 kb)

Video 32.2.

Hand assisted splenectomy (HALS). Targarona (MP4 374061 kb)


  1. 1.
    Park A, Targarona EM, Trias M. Laparoscopic surgery of the spleen: state of the art. Langenbecks J Surg. 2001;386:230–9.CrossRefGoogle Scholar
  2. 2.
    Habermalz B, Sauerland S, Decker G, et al. Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc. 2008;22:821–48.CrossRefPubMedGoogle Scholar
  3. 3.
    Weiss 3rd CA, Kavic SM, Adrales GL, et al. Laparoscopic splenectomy: what barriers remain? Surg Innov. 2005;12:23–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Kaban GK, Czerniach DR, Cohen R, et al. Hand-assisted laparoscopic splenectomy in the setting of splenomegaly. Surg Endosc. 2004;18:1340–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Targarona EM, Balagué C, Trias M. Is the laparoscopic approach reasonable in cases of splenomegaly? Semin Laparosc Surg. 2004;11:185–90.PubMedGoogle Scholar
  6. 6.
    Kant JA, Hubbard SM, Longo DL, et al. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin lymphoma. J Clin Oncol. 1986;4:1419–20.CrossRefGoogle Scholar
  7. 7.
    Moulin-Romsee G, Hindié E, Cuenca X, et al. (18)F FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow thephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.CrossRefPubMedGoogle Scholar
  8. 8.
    Jost LM, Stahel RA, ESMO Guideline Task Force. ESMO minimal clinical recommendation for diagnosis, treatment and follow up of Hodgkin’s disease. Ann Oncol. 2005;16:i54–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Multani P, White CA, Grillo A. Non-Hodgkin lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001;2:279–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Palma M, Kokhaei P, Lundin J, et al. The biology and treatment of chronic lymphocytic leukemia. Ann Oncol. 2006;17:x144–54.CrossRefPubMedGoogle Scholar
  11. 11.
    NCCN. Clinical practice guidelines in oncology™. Non-Hodgkin’s Lymphoma. V.3.2007.
  12. 12.
    Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest. 2007;117:2036–43.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hehlmann R, Hochhaus A, Baccarani M. European leukemia net. Chronic myeloid leukaemia. Lancet. 2007;370:342–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Arana-Yi C, Quintás-Cardama A, Giles F, et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist. 2006;11:929–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004;43:540–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Lopez Monclova J, Targarona Soler E, Peraza Solis Y, et al. Laparoscopic approach for isolated splenic metastasis: comprehensive literature review and report of 6 cases. Surg Laparosc Endosc Percutan Tech. 2013;23:21–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Heniford T, Walsh M. Laparoscopic splenectomy for malignant diseases. In: Greene FL, Heniford B, editors. Minimally invasive cancer management. 1st ed. NY: Springer; 2001. p. 143–55.CrossRefGoogle Scholar
  18. 18.
    Comperat E, Bardier-Dupas A, Camparo P, et al. Splenic metastases: clinicopathologic presentation, differential diagnosis, and pathogenesis. Arch Pathol Lab Med. 2007;131:965–9.PubMedGoogle Scholar
  19. 19.
    Iwase K, Higaki J, Yoon HE, et al. Splenic artery embolization using contour emboli before laparoscopic or laparoscopically assisted splenectomy. Surg Laparosc Endosc Percutan Tech. 2002;12:331–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Martin Arnau B, Turrado Rodriguez V, Tartaglia E, et al. Impact of preoperative platelet count on perioperative outcome after laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Cir Esp. 2016;94:399–403.CrossRefPubMedGoogle Scholar
  21. 21.
    Rodriguez-Otero Luppi C, Targarona Soler EM, Balague Ponz C, et al. Clinical, anatomical, and pathological grading score to predict technical difficulty in laparoscopic splenectomy for non-traumatic diseases. World J Surg. 2017,41:439–448, doi: 10.1007/s00268–016-3683-y.
  22. 22.
    Targarona EM, Balagué C, Trias M. Hand-assisted laparoscopic splenectomy. Semin Laparosc Surg. 2001;8:126–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Targarona EM, Balague C, Cerdan G, et al. Hand-assisted laparoscopic splenectomy (HALS) in cases of splenomegaly: a comparison analysis with conventional laparoscopic splenectomy. Surg Endosc. 2002;16:426–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Targarona EM, Cerdan G, Trias M. Complications of laparoscopic splenectomy. Probl Gen Surg. 2002;19:72–9.CrossRefGoogle Scholar
  25. 25.
    Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg. 2005;24:208–16.CrossRefGoogle Scholar
  26. 26.
    Targarona EM. Portal vein thrombosis after laparoscopic splenectomy: the size of the risk. Surg Innov. 2008;15:266–70.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Julio Lopez Monclova
    • 1
    • 2
  • Carlos Rodriguez Luppi
    • 1
  • Eduardo Mª Targarona Soler
    • 1
  1. 1.Universidad Autónoma de Barcelona, Servicio de Cirugía General y del Aparato Digestivo, Hospital de la Santa Creu i SantpauBarcelonaSpain
  2. 2.Mexican Institute for Social SecurityDeliciasMexico

Personalised recommendations